Medizone International Inc (MZEI) Stock Sentiment Improves

June 27, 2018 - By Ellis Scott

Medizone International, Inc. (OTCMKTS:MZEI) Logo

Sentiment for Medizone International Inc (MZEI)

Medizone International Inc (MZEI) institutional sentiment increased to Infinity in Q1 2018. Its up Infinity, from 0 in 2017Q4. The ratio has increased, as 1 investment professionals started new or increased positions, while 0 reduced and sold equity positions in Medizone International Inc. The investment professionals in our partner’s database now have: 1.19 million shares, up from 97,240 shares in 2017Q4. Also, the number of investment professionals holding Medizone International Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 0 Reduced: 0 Increased: 0 New Position: 1.

Medizone International, Inc. designs, makes, and sells ozone disinfection systems in the United States. The company has market cap of $1.77 million. It offers AsepticSure hospital disinfection system, which is used in decontaminating and sterilizing hospital surgical suites, emergency rooms, and intensive care units, as well as other enclosed spaces, such as gym locker rooms, laboratories, and veterinary clinics. It currently has negative earnings.

The stock increased 25.00% or $0.00085 during the last trading session, reaching $0.00425. About shares traded. Medizone International, Inc. (MZEI) has 0.00% since June 27, 2017 and is . It has underperformed by 12.57% the S&P500.

First National Trust Co holds 0% of its portfolio in Medizone International, Inc. for 13,500 shares. L & S Advisors Inc owns 500,000 shares or 0% of their US portfolio. Moreover, Pnc Financial Services Group Inc. has 0% invested in the company for 17,000 shares. The Pennsylvania-based Vantage Investment Advisors Llc has invested 0% in the stock. Woodley Farra Manion Portfolio Management Inc, a Indiana-based fund reported 26,740 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.